ACETYLCYSTEINE injection, solution Yhdysvallat - englanti - NLM (National Library of Medicine)

acetylcysteine injection, solution

sagent pharmaceuticals - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetylcysteine is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions (5.1)] . risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations]. reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background risk of major birth defects and miscarriage

Acetylcysteine Stirling Anglian 600 mg effervescent tablets Irlanti - englanti - HPRA (Health Products Regulatory Authority)

acetylcysteine stirling anglian 600 mg effervescent tablets

stirling anglian pharmaceuticals ireland limited - acetylcysteine - effervescent tablet - 600 milligram(s) - mucolytics; acetylcysteine

Acetylcysteine Stirling Anglian 600 mg effervescent tablets Irlanti - englanti - HPRA (Health Products Regulatory Authority)

acetylcysteine stirling anglian 600 mg effervescent tablets

stirling anglian pharmaceuticals ltd - acetylcysteine - effervescent tablet - 600 milligram(s) - mucolytics; acetylcysteine

Acetylcysteine Essential-Healthcare 600 mg effervescent tablets Irlanti - englanti - HPRA (Health Products Regulatory Authority)

acetylcysteine essential-healthcare 600 mg effervescent tablets

ascot laboratories (ireland) limited - acetylcysteine - effervescent tablet - mucolytics; acetylcysteine

ACETADOTE- acetylcysteine injection, solution Yhdysvallat - englanti - NLM (National Library of Medicine)

acetadote- acetylcysteine injection, solution

cumberland pharmaceuticals inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetadote is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetadote is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions (5.1)] . risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations]. reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background risk of major birth defects and miscarriage for the indicated po